Comparison between standard and reduced volume radiotherapy in bladder preservation trimodality protocol for muscle-invasive bladder cancer patients

被引:11
|
作者
Arafat, Waleed [1 ,2 ,3 ]
Darwish, Azza [1 ]
Naoum, George E. [2 ]
Sameh, Wael [4 ]
El Husseiny, Gamal [1 ]
Abd-El-Gawad, Fathy [1 ]
Samir, Mostafa [2 ]
机构
[1] Univ Alexandria, Fac Med, Oncol Dept, Alexandria, Egypt
[2] Alexandria Comprehens Canc Ctr, Alexandria, Egypt
[3] Univ Alabama Birmingham, 1720 2nd Ave S, Birmingham, AL 35233 USA
[4] Univ Alexandria, Urol Dept, Fac Med, Alexandria, Egypt
来源
ECANCERMEDICALSCIENCE | 2016年 / 10卷
关键词
bladder cancer; lymph nodes; radiotherapy; trimodality protocol;
D O I
10.3332/ecancer.2016.682
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: Our aim is to compare the toxicity, pelvic nodal relapse, and overall survival of whole bladder irradiation only to the standard technique of whole pelvis irradiation followed by bladder boost in patients with muscle-invasive bladder carcinoma undergoing bladder preservation protocol. Material and method: A total of 60 patients with transitional cell carcinoma, stage T2-3, N0, M0 bladder cancer were subjected to maximal transurethral resection bladder tumour (TURB). Then, the patients were randomised into two groups: group I (30 patients) to receive whole pelvis radiotherapy 44 Gy followed by 20 Gy bladder boost. While group II (30 patients) were randomised to receive whole bladder radiotherapy alone for a total dose of 64 Gy. In both groups, concomitant cisplatin and paclitaxel were given weekly throughout the whole course of radiotherapy where conventional 2 Gy/fraction were used. Additionally, four cycles of adjuvant cisplatin and paclitaxel were given after the end of the chemoradiotherapy induction course. Results: The first assessment after the induction chemoradiotherapy showed that complete response was achieved in 73.3% of patients in group I and 76.7% of the patients in group II. After a median follow-up of 2 years, regional relapse occurred in 7.1% of patients in group I and 10.3% in group II. (p = 1). Distant metastases were detected in 17.9% of patient in group I and 13.8% in group II (p = 0.73). The 2-year disease-free survival was 60% in group I and 63.3% in group II (p = 0.79). The whole 2-year overall survival was 75% in group I and 79.3% in group II (p = 0.689). Radiation gastrointestinal (GI) acute toxicity was higher in group I than in group II (p = 0.001), while late GI radiation toxicity was comparable in both groups. Conclusion: Treating the bladder only, without elective pelvic nodal irradiation, did not compromise pelvic control rate, but significantly decreased the acute radiation toxicity.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Stereotactic Radiotherapy Boost as Part of Tri-Modality Treatment for Bladder Preservation in Patients with Muscle-Invasive Bladder Cancer
    Qin, S. B.
    Gao, X. S.
    Zhang, C. J.
    Li, H. Z.
    Yu, W.
    Hao, H.
    Yao, L.
    He, Z. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E205 - E206
  • [32] Organ Preservation with Definitive Radiotherapy for Elderly Patients with Muscle-Invasive Bladder Carcinoma
    Gergelis, K. R.
    Kreofsky, C. R.
    Choo, C. S.
    Lester, S. C.
    Viehman, J.
    Pisansky, T. M.
    Davis, B. J.
    Stish, B. J.
    Choo, C. R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E251 - E252
  • [33] Trimodality Therapy for Muscle-Invasive Bladder Cancer: Concurrent Chemotherapy is Not Enough
    Winquist, Eric
    Booth, Christopher M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (24) : 2709 - +
  • [34] Trimodality Therapy With or Without Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer
    Royce, Trevor J.
    Liu, Yuan
    Milowsky, Matthew, I
    Efstathiou, Jason A.
    Jani, Ashesh B.
    Fischer-Valuck, Benjamin
    Patel, Sagar A.
    CLINICAL GENITOURINARY CANCER, 2021, 19 (04) : 362 - 368
  • [35] Genomic Determinants of Response to Trimodality Therapy for Muscle-Invasive Bladder Cancer
    Kamran, S. C.
    Zhou, Y.
    Otani, K.
    Drumm, M. R.
    Otani, Y.
    Wu, S.
    Wu, C. L.
    Borger, D.
    Lennerz, J. K.
    Van Allen, E. M.
    Willers, H.
    Hong, T. S.
    Liu, Y.
    Davicioni, E.
    Gibb, E.
    Shipley, W. U.
    Mouw, K. W.
    Efstathiou, J. A.
    Miyamoto, D. T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : S24 - S24
  • [36] MicroRNA Biomarkers for Patients With Muscle-Invasive Bladder Cancer Undergoing Selective Bladder-Sparing Trimodality Treatment
    Meng, Wei
    Efstathiou, Jason
    Singh, Rajbir
    McElroy, Joseph
    Volinia, Stefano
    Cui, Ri
    Ibrahim, Ahmed
    Johnson, Benjamin
    Gupta, Nirmala
    Mehta, Satvam
    Wang, Huabao
    Miller, Eric
    Phuong Nguyen
    Fleming, Jessica
    Wu, Chin-Lee
    Haque, S. Jaharul
    Shipley, William
    Chakravarti, Arnab
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 104 (01): : 197 - 206
  • [37] Organ preservation in muscle-invasive urothelial bladder cancer
    Niglio, Scot A.
    Purswani, Juhi M.
    Schiff, Peter B.
    Lischalk, Jonathan W.
    Huang, William C.
    Murray, Katie S.
    Apolo, Andrea B.
    CURRENT OPINION IN ONCOLOGY, 2024, 36 (03) : 155 - 163
  • [38] Impact of facility patient volume on overall survival in patients with muscle invasive bladder cancer undergoing trimodality bladder preservation therapy.
    Fischer-Valuck, Benjamin Walker
    Rudra, Soumon
    Gabani, Prashant
    Mueller, Ryan
    Gay, Hiram Alberto
    Michalski, Jeff M.
    Abraham, Christopher
    Baumann, Brian Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [39] Impact of Facility Radiation Patient Volume on Overall Survival in Patients with Muscle Invasive Bladder Cancer Undergoing Trimodality Bladder Preservation Therapy
    Fischer-Valuck, Benjamin W.
    Rudra, Soumon
    Gabani, Prashant
    Brenneman, Randall
    Mueller, Ryan
    Chin, Walter
    Gay, Hiram A.
    Michalski, Jeff M.
    Abraham, Christopher
    Baumann, Brian C.
    BLADDER CANCER, 2019, 5 (03) : 235 - 244
  • [40] Single institutional experience of bladder-preserving trimodality treatment for muscle-invasive bladder cancer
    Joung, Jae Young
    Han, Kyung Seok
    Kim, Taek Sang
    Seo, Ho Kyung
    Chung, Jinsoo
    Lee, Kang Hyun
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2008, 23 (04) : 598 - 603